Sponsor or institution

Clinical trials and research at Neurocrine Biosciences

• 14Clinical trials
• 24Countries

Newest trials

All recruiting trials (14)

• Crinecerfont safety testing in babies with classic CAH under 4 years old

  This study tests whether crinecerfont is safe and tolerable in children under 4 years with classic CAH who have been on hydrocortisone.

  Recruiting at 11 sites Phase 2 Neurocrine Biosciences · San Francisco, California and 10 other locations · NCT07536269

• NBI-1065890 versus placebo for adults with tardive dyskinesia

  This trial will test if NBI-1065890 reduces involuntary movements in adults with tardive dyskinesia compared with a placebo.

  Recruiting at 18 sites Phase 2 Neurocrine Biosciences · Bryant, Arkansas and 17 other locations · NCT07365462

• NBI-1117570 for adults hospitalized with schizophrenia

  This study will see if NBI-1117570 helps reduce behavioral and psychological symptoms in adults with schizophrenia who need hospitalization, compared with a placebo.

  Recruiting at 6 sites Phase 2 Neurocrine Biosciences · Kazanlak and 5 other locations · NCT07288333

• NBI-1117568 for adults with Bipolar I disorder experiencing current mania

  This trial will test whether NBI-1117568 reduces manic symptoms in adults with Bipolar I disorder who are currently having a manic episode.

  Recruiting at 11 sites Phase 2 Neurocrine Biosciences · Little Rock, Arkansas and 10 other locations · NCT07288320

• NBI-1117568 to prevent relapse in adults with schizophrenia

  This will test whether continuing NBI-1117568 helps prevent symptom relapse in adults with schizophrenia who showed a stable response during an initial open-label treatment.

  Recruiting at 23 sites Phase 3 Neurocrine Biosciences · Garden Grove, California and 24 other locations · NCT07227818

• NBI-1065845 as an adjunctive maintenance treatment for major depressive disorder

  This Phase 3 test will see if adding NBI-1065845 to a person’s current oral antidepressant helps delay relapse in people with recurrent major depressive disorder who have not responded adequately to their current medication.

  Recruiting at 55 sites Phase 3 Neurocrine Biosciences · Oceanside, California and 60 other locations · NCT07196501

• Long-term treatment with NBI-1117568 for adults with schizophrenia

  This trial tests whether long-term treatment with NBI-1117568 is safe for adults living with schizophrenia.

  Recruiting at 55 sites Phase 3 Neurocrine Biosciences · Bryant, Arkansas and 60 other locations · NCT07114874

• Valbenazine for adults with tardive dyskinesia who remain symptomatic on or after a VMAT2 inhibitor

  This trial will test whether valbenazine reduces involuntary movements in adults with tardive dyskinesia who still have symptoms while taking or after stopping a VMAT2 inhibitor.

  Recruiting at 19 sites Phase 4 Neurocrine Biosciences · Bryant, Arkansas and 18 other locations · NCT07105111

• NBI-1117568 for adults hospitalized with schizophrenia

  This trial will test whether NBI-1117568 helps improve behavioral and psychological symptoms in adults hospitalized for worsening schizophrenia compared with a placebo.

  Recruiting at 15 sites Phase 3 Neurocrine Biosciences · Little Rock, Arkansas and 19 other locations · NCT07105098

• Long-term safety and tolerability of NBI-1065845 added to antidepressants for major depression

  This will test whether taking NBI-1065845 alongside regular oral antidepressants is safe and tolerable long-term for adults with major depressive disorder who haven't responded well to treatment.

  Recruiting at 106 sites Phase 3 Neurocrine Biosciences · Huntsville, Alabama and 119 other locations · NCT06966401

• Evaluating NBI-1117568 for treating schizophrenia in hospitalized adults

  This study is testing a new medication called NBI-1117568 to see if it can help improve symptoms of schizophrenia in adults who are currently hospitalized.

  Recruiting at 21 sites Phase 3 Neurocrine Biosciences · Bryant, Arkansas and 20 other locations · NCT06963034

• NBI-1065845 added to a current antidepressant for major depressive disorder

  This trial will test whether adding NBI-1065845 to a stable oral antidepressant helps adults with major depressive disorder who have not had enough benefit.

  Recruiting at 28 sites Phase 3 Neurocrine Biosciences · Chino, California and 34 other locations · NCT06963021

• Assessing NBI-1065845 for treating major depressive disorder

  This study is testing a new treatment called NBI-1065845 to see if it can help people with major depression who haven't felt better with their current medications.

  Recruiting at 34 sites Phase 3 Neurocrine Biosciences · Huntsville, Alabama and 38 other locations · NCT06911112

• Evaluating NBI-1065845 for treating major depressive disorder

  This study is testing a new treatment called NBI-1065845 to see if it can help people with major depressive disorder who haven't felt better with their current antidepressants.

  Recruiting at 13 sites Phase 3 Neurocrine Biosciences · Little Rock, Arkansas and 17 other locations · NCT06786624

Quick answers

How many clinical trials run by Neurocrine Biosciences are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in United States (13 trials), Bulgaria (6 trials), Romania (5 trials), Serbia (5 trials), Canada (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 9, Phase 2: 4, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →